AZN

AstraZeneca
NYSE

Real-time Quotes | Nasdaq Last Sale

44.66
+0.81
+1.85%
After Hours: 44.66 0 0.00% 16:53 04/09 EDT
OPEN
43.91
PREV CLOSE
43.85
HIGH
44.98
LOW
43.50
VOLUME
5.63M
TURNOVER
--
52 WEEK HIGH
51.55
52 WEEK LOW
36.15
MARKET CAP
117.20B
P/E (TTM)
86.45
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average AZN stock price target is 53.05 with a high estimate of 57.00 and a low estimate of 48.50.

EPS

AZN News

More
  • Clovis Oncology Analyst Turns Bearish Ahead Of PDUFA Date For Rubraca
  • Benzinga · 1d ago
  • Clovis Oncology Analyst Turns Bearish Ahead Of PDUFA Date For Rubraca
  • Benzinga · 1d ago
  • Better Coronavirus Stock: Inovio vs. Regeneron
  • MotleyFool.com · 1d ago
  • Is mRNA the Key to a Coronavirus Vaccine?
  • MotleyFool.com · 1d ago

Industry

Pharmaceuticals
+0.59%
Pharmaceuticals & Medical Research
+0.82%

Hot Stocks

Symbol
Price
%Change

About AZN

AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.
More

Webull offers kinds of AstraZeneca plc stock information, including NYSE:AZN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AZN stock news, and many more online research tools to help you make informed decisions.